Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients.
immune-related adverse events
immunotherapy
octogenarians
older patients
overall survival
progression-free survival
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
11
01
2024
revised:
25
02
2024
accepted:
26
02
2024
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
28
3
2024
Statut:
epublish
Résumé
The development of immunotherapy checkpoint inhibitors (ICIs) has revolutionized cancer care. However, old patients are underrepresented in most clinical trials, although they represent a significant proportion of real-world patients. We aimed to evaluate the effectiveness and safety of ICIs in patients older than the age of 70. We performed a retrospective chart review of 145 patients aged 70 or older treated with ICIs for metastatic or unresectable cancer. Median progression-free survival (PFS) was 10.4 months (95% CI 8.6-13.7), with no differences between octogenarians and septuagenarians ( The effectiveness of ICIs in older cancer patients primarily depends on the line of treatment and treatment discontinuation. Octogenarians experienced similar treatment responses, PFS, OS, and adverse effects compared to septuagenarians.
Sections du résumé
BACKGROUND
BACKGROUND
The development of immunotherapy checkpoint inhibitors (ICIs) has revolutionized cancer care. However, old patients are underrepresented in most clinical trials, although they represent a significant proportion of real-world patients. We aimed to evaluate the effectiveness and safety of ICIs in patients older than the age of 70.
METHODS
METHODS
We performed a retrospective chart review of 145 patients aged 70 or older treated with ICIs for metastatic or unresectable cancer.
RESULTS
RESULTS
Median progression-free survival (PFS) was 10.4 months (95% CI 8.6-13.7), with no differences between octogenarians and septuagenarians (
CONCLUSION
CONCLUSIONS
The effectiveness of ICIs in older cancer patients primarily depends on the line of treatment and treatment discontinuation. Octogenarians experienced similar treatment responses, PFS, OS, and adverse effects compared to septuagenarians.
Identifiants
pubmed: 38541020
pii: jpm14030278
doi: 10.3390/jpm14030278
pii:
doi:
Types de publication
Journal Article
Langues
eng